Catalyst Wire Dossier Catalyst Wire Dossier

NBI-74788 (Crinecerfont)

Crinecerfont · Neurocrine Biosciences
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for NBI-74788 (Crinecerfont), covering 2024-07-18 to 2024-07-18. Get the full timeline:

Most recent: Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia [Phase 2]

See pricing